FENNEC PHARMACEUTICALS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $31.97M.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2017-06-30 was $7.57M, a 51.42% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2016-06-30 was $5.00M.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2025 was $42.05M.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2020 was $31.97M.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2017 was $27.38M, a 447.62% increase from fiscal 2016.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2016 was $5.00M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $42.05M 10-K · filed 2026-03-27 | |
| 2020-12-31 | $31.97M 10-K · filed 2022-02-28 | |
| 2020-06-30 | $31.97M 10-Q · filed 2021-11-10 | |
| 2017-12-31 | $27.38M 10-K · filed 2019-03-15 | |
| 2017-06-30 | $7.57M 10-Q · filed 2017-11-13 | |
| 2016-12-31 | $5.00M 10-K · filed 2018-03-28 | |
| 2016-06-30 | $5.00M 10-Q · filed 2017-05-12 | |
| 2014-12-31 | $2.18M 10-K · filed 2016-03-28 | |
| 2013-12-31 | $1.57M 10-Q · filed 2015-11-12 | |
| 2000-06-30 | $793.00K 10-Q · filed 2014-11-13 | |
| 1999-06-30 | $1.61M 10-Q · filed 2014-11-13 | |
| 1997-06-30 | $0.00 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |